Merck Named To 2013 Working Mother 100 Best Companies


September 17, 2013 1:20 pm ET

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has been named as one of the Working Mother 100 Best Companies for 2013.

Honored on the list for the 26th year, Merck is among the 100 companies recognized for their commitment to progressive workplace programs, including female representation, compensation, child care, flexibility, time off and leave, family-friendly programs and company culture. Those chosen also demonstrated their commitment to supporting working moms to be healthy.

“This award recognizes Merck’s commitment to fostering an environment where all employees, including working parents and those who provide care for others, can effectively integrate work and life, take care of themselves and their families and reach their professional goals,” said Dottie Brienza, Chief Diversity Officer and Executive Talent Leader, Merck.

Merck provides employees with a number of tools, programs and resources that promote health and wellness. The company offers a complete suite of flexible work arrangements for employees and their families to support an inclusive and welcoming environment. Some of these arrangements include flex time, job rotation, job share programs, child care centers, dependent care solutions, a college coach, a special needs program, and online caregiver support.

The 100 Best Companies are featured in the October/November issue of Working Mother and on

About Merck

Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside of the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit and connect with us on Twitter, Facebook and YouTube

Merck Forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.  

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2012 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (

# # #


Maria Tortoreto, 908-423-4598
Justin Holko, 908-423-5088

Unsubscribe from email alerts